Capstone Investment Advisors
KURA icon

Capstone Investment Advisors’s Kura Oncology KURA Stock Holding History

Capstone Investment Advisors’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-13,517
Closed -$278K – 2075
2024
Q2 		$278K Buy
+13,517
New +$278K ﹤0.01% 1614

Other funds holding KURA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capstone Investment Advisors's KURA Position: Q3 2024 in Review

Capstone Investment Advisors sold out of Kura Oncology (KURA) in Q3 2024, closing a stake of 13,517 shares — an estimated $278K sold.

Capstone Investment Advisors first reported a position in KURA in Q2 2024 and held it in 1 quarter. The position peaked at $278K in Q2 2024. 179 funds tracked by Wall St. Rank hold KURA as of Q3 2024.

  • Capstone Investment Advisors reported no remaining Kura Oncology position as of Q3 2024 after selling out during the quarter.
  • Capstone Investment Advisors sold 13,517 Kura Oncology shares in Q3 2024, an estimated $278K.
  • Capstone Investment Advisors first reported a position in Kura Oncology in Q2 2024 and held it in 1 quarter.
  • Capstone Investment Advisors's Kura Oncology position peaked at $278K in Q2 2024.
  • 179 funds tracked by Wall St. Rank held Kura Oncology as of Q3 2024.

Based on Capstone Investment Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.